Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 600,700 shares, a decrease of 51.9% from the December 15th total of 1,250,000 shares. Approximately 7.3% of the shares of the stock are sold short. Based on an average trading volume of 4,890,000 shares, the days-to-cover ratio is presently 0.1 days.
Separately, TheStreet upgraded Cumberland Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Monday, December 6th.
Shares of Cumberland Pharmaceuticals stock opened at $3.99 on Friday. Cumberland Pharmaceuticals has a one year low of $2.20 and a one year high of $7.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.06 and a current ratio of 2.63. The stock’s 50-day moving average is $3.98 and its 200 day moving average is $3.27.
A number of large investors have recently made changes to their positions in CPIX. Morgan Stanley boosted its holdings in Cumberland Pharmaceuticals by 131.3% in the first quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 6,335 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Cumberland Pharmaceuticals by 2.4% in the second quarter. Dimensional Fund Advisors LP now owns 755,500 shares of the specialty pharmaceutical company’s stock worth $2,149,000 after acquiring an additional 17,619 shares in the last quarter. Berkshire Asset Management LLC PA lifted its holdings in shares of Cumberland Pharmaceuticals by 3.2% in the second quarter. Berkshire Asset Management LLC PA now owns 170,830 shares of the specialty pharmaceutical company’s stock valued at $486,000 after purchasing an additional 5,335 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Cumberland Pharmaceuticals in the third quarter valued at approximately $32,000. Institutional investors and hedge funds own 18.69% of the company’s stock.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
Featured Story: The Structure of a Futures Contract
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.